Efficacy of Lasmiditan Across Patient and Migraine Characteristics in Japanese Patients with Migraine- A Secondary Analysis of the MONONOFU Trial

Takao Takeshima¹, Mika Komori², Yuka Tanji², Akichika Ozeki², Yoshihisa Tatsuoka³

¹Tominaga Hospital, Osaka, Japan; ²Eli Lilly Japan K.K., Kobe, Japan; ³Tatsuoka Neurology Clinic, Kyoto, Japan

Corresponding author

Mika Komori

Email: komori_mika@lilly.com
### Supplementary Table 1: Proportion of triptan insufficient responders across treatment groups

| Triptan IR subgroups                                                                 | Lasmiditan 50 mg N=20 | Lasmiditan 100 mg N=49 | Lasmiditan 200 mg N=47 | Placebo N=56 | Total N=172 |
|--------------------------------------------------------------------------------------|-----------------------|------------------------|------------------------|--------------|-------------|
| 1. Overall response none/poor (based on the most recent triptan), n (%)              | 3 (15.0)              | 10 (20.4)              | 9 (19.1)               | 7 (12.5)     | 29 (16.9)   |
| 2. Inconsistent response (based on the most recent triptan), n (%)                   | 0 (0.0)               | 0 (0.0)                | 0 (0.0)                | 1 (1.8)      | 1 (0.6)     |
| 3. Triptan discontinuer\(^a\), n (%)                                                | 0 (0.0)               | 1 (2.0)                | 0 (0.0)                | 3 (5.4)      | 4 (2.3)     |
| 4. mTOQ\(^b\) poor response at Visit 2 (baseline), n (%)                           | 17 (85.0)             | 39 (79.6)              | 39 (83.0)              | 45 (80.4)    | 140 (81.4)  |
| 5. Triptan-contraindicated patients, n (%)                                          | 1 (5.0)               | 0 (0.0)                | 0 (0.0)                | 4 (7.1)      | 5 (2.9)     |

\(^a\)Defined as patients who had lack of pain freedom or pain relief at 2 hours, had no return to function, had inconsistent response, migraine recurrence, intolerance to medication, no relief from symptoms, or discontinued due to cardiovascular diseases or risk factors or contraindication.

\(^b\)Baseline mTOQ was summarized as follows: Never (0 points); Rarely (0 points); Less than half the time (1 point); and Half the time or more (2 points). A total score from 0 to 8 is calculated by summing the points from 4 of the items (2-hour pain free, sustained 24-hour pain relief, comfortable to make plans, and perceived control), which define categories of acute treatment response: very poor (0), poor (1-5), moderate (6-7), and maximum (8) treatment efficacy.

IR, insufficient responder; mTOQ, migraine Treatment Optimization Questionnaire; N, total number of patients in the specified group; n, total number of patients in the subgroup.